Eli Lilly's Diabetes & Weight Loss Pill Replaces Injections
Eli Lilly is developing Orforglipron oral pills for weight loss and type 2 diabetes that could replace injections, making treatment more accessible and convenient for millions.
Category : Search result: Eli Lilly Orforglipron
Eli Lilly Ups Forecast as Zepbound Demand Soars
Pharmaceutical giant Eli Lilly raises full-year profit forecast as demand skyrockets for revolutionary weight-loss treatment Zepbound, sending shares climbing 7%.
Israeli Foreign Minister Cohen to Visit India Next Week
Israeli Foreign Minister Eli Cohen embarks on crucial India visit to bolster bilateral relations, discuss defense cooperation, and address regional security concerns amid growing Middle East tensions.
Eli Lilly & NVIDIA Partner for AI Drug Discovery
Pharmaceutical giant Eli Lilly partners with NVIDIA to deploy cutting-edge AI supercomputers that will accelerate drug development and transform pharmaceutical research.
Cipla Shares Fall 3% Despite Eli Lilly Weight Loss Drug Deal
Cipla's stock faces unexpected pressure despite securing rights to manufacture and distribute Eli Lilly's revolutionary weight loss drug Mounjaro in India. Discover why investors remain cautious.
Lilly-Cipla Partnership Expands Weight Loss Therapy Access
In a groundbreaking move, Eli Lilly partners with Cipla to dramatically expand availability of innovative weight loss therapies across India, addressing the growing obesity crisis.
Cipla-Eli Lilly deal brings weight loss drugs to India
Indian pharmaceutical giant Cipla announces landmark deal with Eli Lilly to manufacture and distribute popular weight loss medications Mounjaro and Zepbound in India under different brand names.
Eli Lilly-Cipla Partner for Weight Loss Drugs in India
Pharma giant Eli Lilly collaborates with Indian partner Cipla to introduce groundbreaking obesity and diabetes treatments Mounjaro and Yurpeak in the Indian market, expanding access to innovative weight management solutions.
Page 1 of 1